Evidence map›Paper›PMID 34683456›Full record

ArticleMicroorganisms2021

Prevalence and Risk Factors for ESBL/AmpC-

Laura Patricia Weber, Sylvia Dreyer, Maike Heppelmann, Katharina Schaufler, Timo Homeier-Bachmann, Lisa Bachmann

Open access · goldAbstract read
In one paragraph

Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Risk Factors for ESBL-ProducingVeterinary medicine international · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Highly Virulent and Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2022
    Article
  14. Distribution of ESBL/AmpC-Antibiotics (Basel, Switzerland) · 2022
    Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Laura Patricia WeberAlta Deutschland GmbH, 29525 Uelzen, Germany.
Sylvia DreyerFriedrich-Loeffler-Institut, Institute of International Animal Health/One Health, Greifswald-Insel Riems, 17493 Greifswald, Germany.ORCID 0000-0002-7403-9755
Maike HeppelmannClinic for Cattle, University of Veterinary Medicine Hannover, Foundation, 30173 Hannover, Germany.
Katharina SchauflerInstitute of Pharmacy, Universität Greifswald, 17475 Greifwald, Germany.ORCID 0000-0002-2669-8799
Timo Homeier-BachmannFriedrich-Loeffler-Institut, Institute of Epidemiology, Greifswald-Insel Riems, 17493 Greifswald, Germany.ORCID 0000-0002-8135-3814
Lisa BachmannAlta Deutschland GmbH, 29525 Uelzen, Germany.
Friedrich-Loeffler-Institut · DEUniversity of Veterinary Medicine Hannover, Foundation · DEAltana (Germany) · DEUniversitätsmedizin Greifswald · DE

Funding

Friedrich-Loeffler-Institute (Internal Fund) HR-0059
6 · The paper itself

Abstract

The objectives of this study were to ascertain the fecal ESBL/AmpC-

Indexed as

antimicrobial resistancecalvescattleESBL/AmpC-E. coli

Identifiers

PMID34683456
PMCPMC8539614
OpenAlexW3206777918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.